Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)
Shots:
- Bio-Thera and STADA have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab)
- Under the collaboration, Bio-Thera is entitled to receive a $10M upfront and an additional $147.5M development and commercial milestones upon certain conditions fulfilment
- Furthermore, Bio-Thera will handle the development, manufacturing and supply activities of BAT2506, while STADA gains an exclusive right to commercialize it across the EU, UK, Switzerland and other selected regions
Ref: Bio-Thera | Image: Bio-Thera
Related News:- Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar- golimumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
